Free Trial

Exagen (XGN) Stock Price, News & Analysis

Exagen logo
$9.85 +0.11 (+1.16%)
Closing price 03:59 PM Eastern
Extended Trading
$9.86 +0.00 (+0.02%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Exagen Stock (NASDAQ:XGN)

Key Stats

Today's Range
$9.59
$10.00
50-Day Range
$6.74
$10.10
52-Week Range
$2.38
$10.34
Volume
103,006 shs
Average Volume
231,131 shs
Market Capitalization
$216.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25
Consensus Rating
Buy

Company Overview

Exagen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

XGN MarketRank™: 

Exagen scored higher than 74% of companies evaluated by MarketBeat, and ranked 271st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Exagen has only been the subject of 4 research reports in the past 90 days.

  • Read more about Exagen's stock forecast and price target.
  • Earnings Growth

    Earnings for Exagen are expected to grow in the coming year, from ($0.88) to ($0.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exagen is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exagen is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exagen has a P/B Ratio of 10.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exagen's valuation and earnings.
  • Percentage of Shares Shorted

    10.41% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Exagen has recently increased by 52.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Exagen does not currently pay a dividend.

  • Dividend Growth

    Exagen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.41% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Exagen has recently increased by 52.83%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Exagen has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Exagen this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Exagen to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exagen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.60% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exagen's insider trading history.
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XGN Stock News Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
BTIG Sticks to Their Buy Rating for Exagen (XGN)
Exagen (XGN) Receives a Buy from Craig-Hallum
Exagen Inc. Reports Record Revenue Amidst Growth Challenges
See More Headlines

XGN Stock Analysis - Frequently Asked Questions

Exagen's stock was trading at $4.10 at the beginning of 2025. Since then, XGN stock has increased by 140.3% and is now trading at $9.8530.

Exagen Inc. (NASDAQ:XGN) announced its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). The company earned $17.20 million during the quarter, compared to analysts' expectations of $16.25 million. Exagen had a negative net margin of 28.85% and a negative trailing twelve-month return on equity of 130.38%.
Read the conference call transcript
.

Exagen (XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

Top institutional shareholders of Exagen include Balyasny Asset Management L.P. (3.27%), Kennedy Capital Management LLC (1.41%), Russell Investments Group Ltd. (1.00%) and FourWorld Capital Management LLC (0.95%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, James L L Tullis, John Aballi, Kamal Adawi and Mark Hazeltine.
View institutional ownership trends
.

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F).

Company Calendar

Last Earnings
7/29/2025
Today
8/29/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Healthcare
Current Symbol
NASDAQ:XGN
CIK
1274737
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$10.00
Potential Upside/Downside
+15.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.11 million
Net Margins
-28.85%
Pretax Margin
-28.76%
Return on Equity
-130.38%
Return on Assets
-34.69%

Debt

Debt-to-Equity Ratio
1.06
Current Ratio
4.95
Quick Ratio
4.95

Sales & Book Value

Annual Sales
$55.64 million
Price / Sales
3.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.96 per share
Price / Book
10.15

Miscellaneous

Outstanding Shares
22,000,000
Free Float
19,231,000
Market Cap
$214.28 million
Optionable
Optionable
Beta
1.61

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:XGN) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners